Prostatic arterial embolization versus holmium laser enucleation of the prostate: 1-year outcomes
- PMID: 36451037
- DOI: 10.1007/s00345-022-04225-7
Prostatic arterial embolization versus holmium laser enucleation of the prostate: 1-year outcomes
Abstract
Purpose: Holmium Laser Enucleation of the Prostate (HoLEP) and Prostatic Artery Embolization (PAE) are novel techniques for the treatment of benign prostatic hyperplasia lower urinary tract symptoms (BPH-LUTS). The objective of this study was to describe and compare the functional results and complications of these two techniques at one year follow-up.
Materials and methods: We performed a retrospective, monocentric study of all patients consecutively treated in our center with HoLEP or PAE for symptomatic or complicated BPH between January 2016 and December 2019. Data regarding patient and perioperative characteristics, follow-up biological results, functional questionnaires and uroflowmetry were collected from medical records.
Results: A total of 490 and 57 patients were treated with HoLEP and PAE, respectively. The demographic and clinical characteristics of the two groups were similar. The operative time was significantly higher for PAE (p < 0.001) and hospitalization time longer after HoLEP (p = 0.0006). The urinary catheterization time was longer after PAE (p < 0.001). The prostatic volume treated was higher with HoLEP than with PAE (56% versus 26%, p < 0.001). The mean difference in IPSS from baseline to 12 months was significantly higher after HoLEP than after PAE: - 17.58 versus - 8 (p < 0.001). The mean difference in QoL-IPSS from baseline to 12 months was significantly higher after HoLEP: - 4.09 versus - 2.27 (p < 0.001). The rate of postoperative adverse events in the first three months was similar between the two groups:35% after HoLEP and 33% after PAE (p = 0.88).
Conclusions: HoLEP and PAE both significantly improved BPH-LUTS, with HoLEP having an advantage over PAE.
Keywords: Benign prostatic hyperplasia; Holmium laser enucleation of the prostate; IPSS; Lower urinary tract symptoms; Prostate surgery; Prostatic arterial embolization.
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
References
-
- Ahyai SA, Lehrich K, Kuntz RM (2007) Holmium laser enucleation versus transurethral resection of the prostate: 3-year follow-up results of a randomized clinical trial. Eur Urol 52:1456–1463. https://doi.org/10.1016/j.eururo.2007.04.053 - DOI
-
- Kuntz RM, Lehrich K, Ahyai SA (2008) Holmium laser enucleation of the prostate versus open prostatectomy for prostates greater than 100 grams: 5-year follow-up results of a randomised clinical trial. Eur Urol 53:160–166. https://doi.org/10.1016/j.eururo.2007.08.036 - DOI
-
- Lerner LB, McVary KT, Barry MJ et al (2021) Management of lower urinary tract symptoms attributed to benign prostatic hyperplasia: AUA GUIDELINE PART II-surgical evaluation and treatment. J Urol 206:818–826. https://doi.org/10.1097/JU.0000000000002184 - DOI
-
- Pisco JM, Bilhim T, Pinheiro LC et al (2016) Medium- and long-term outcome of prostate artery embolization for patients with benign prostatic hyperplasia: results in 630 patients. J Vasc Interv Radiol 27:1115–1122. https://doi.org/10.1016/j.jvir.2016.04.001 - DOI
-
- Shim SR, Kanhai KJK, Ko YM, Kim JH (2017) Efficacy and safety of prostatic arterial embolization: systematic review with meta-analysis and meta-regression. J Urol 197:465–479. https://doi.org/10.1016/j.juro.2016.08.100 - DOI
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
